Uncontrolled cellular division is the defining hallmark of malignancy. Historically, conventional cytotoxic chemotherapies have attempted to eliminate cancer cells by indiscriminately damaging DNA or disrupting microtubules during mitosis. However, a more precise and increasingly prominent therapeutic paradigm focuses on arresting the cell cycle engine at specific regulatory gates. By understanding the molecular mechanics of these checkpoints, researchers can either freeze cancer cells in a state of permanent dormancy or force them into lethal, premature division.
Freezing Replication at the G0/G1 and G1/S Transitions
Before a cell can replicate its genome, it must pass through the G1 checkpoint. Halting cells at this stage prevents the initiation of DNA synthesis, effectively forcing them into a quiescent or senescent state.
The cyclin D–CDK4/6 axis is a primary engine of this transition. As demonstrated by Pin Zhang et al. in their clinical evaluation of the CDK4/6 inhibitor dalpiciclib, selectively blocking these kinases provides a robust clinical brake against tumor proliferation in hormone receptor-positive breast cancers (A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer). Similarly, downstream components of the mTOR pathway, such as Cyclin D1, can be targeted to induce a state of cellular dormancy rather than immediate apoptosis, as shown by Li Wang et al. using the mTOR inhibitor temsirolimus (Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma).
Other metabolic and signaling pathways converge on this same gate. For instance, He Wang et al. demonstrated that metformin leverages the AMPK/autophagy pathway to downregulate Cyclin D1 and PCNA, trapping aggressive prostate cancer cells in G0/G1 (Metformin exerts anti-AR-negative prostate cancer activity via AMPK/autophagy signaling pathway). At the genetic level, Jinah Kim established that inhibiting Tousled-like kinase 2 (TLK2) stabilizes the cell cycle inhibitor p27, which effectively blocks the G1/S transition and halts proliferation (Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers).
The G2/M Gatekeeper: Preventing Mitotic Entry
If a cell successfully replicates its DNA, it faces a second major gatekeeper: the G2/M checkpoint. This boundary ensures the cell does not enter mitosis until it is sufficiently prepared and any genomic errors are resolved.
The core engine driving entry into mitosis is the CDK1/Cyclin B1 kinase complex. Pharmacologically downregulating or inhibiting this complex stalls the cell cycle right at the threshold of division. Jia Liu et al. demonstrated that downregulating CDK1/Cyclin B1 traps head and neck carcinoma cells in the G2/M phase, preventing them from dividing (Fenofibrate Increases Radiosensitivity in Head and Neck Squamous Cell Carcinoma via Inducing G2/M Arrest and Apoptosis). This transition is also tightly regulated by upstream phosphatases like CDC25B, which normally activates CDK1. By deploying targeted degraders against CDC25B, Yangjiong Xiao et al. achieved sustained G2/M arrest and subsequent apoptosis in ovarian cancer models (Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer).
Furthermore, structural elements of the mitotic machinery itself can be targeted to trigger this checkpoint. Yuchong Peng showed that disrupting the stability of Polo-like kinase 1 (PLK1)—a master regulator of chromosome alignment—prevents proper metaphase plate organization, activating cellular checkpoints that freeze cells in G2/M (USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis).
Exploiting Checkpoint Abrogation for Mitotic Catastrophe
While inducing arrest can halt tumor growth, an alternative, highly potent strategy involves breaking the checkpoint entirely when DNA damage is present.
Normally, the G2/M checkpoint serves as a protective mechanism, allowing cancer cells to pause and repair genomic damage inflicted by chemotherapies. By intentionally inhibiting master checkpoint regulators like Checkpoint kinase-1 (CHK1), therapies can override this pause. Zhuoyi Fan et al. demonstrated that combining CHK1 inhibition with etoposide prevents cells from halting to repair DNA, forcing them into premature mitosis with fragmented genomes—a lethal state known as mitotic catastrophe (Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair).
This concept of induced synthetic lethality is further supported by Shaolu Zhang et al., who showed that suppressing homologous recombination repair while simultaneously disrupting the G2/M checkpoint forces glioblastoma cells to undergo catastrophic mitosis, triggering widespread apoptosis (BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair).
Radiosensitization via Cell Cycle Synchronization
Why does trapping cells at the G2/M boundary make them so vulnerable to external therapies? The answer lies in the changing physical and biochemical state of the cell throughout its cycle.
Cells are most susceptible to ionizing radiation and certain DNA-damaging agents during the G2 and M phases, when their chromatin is condensing and they lack the time to execute complex repair pathways before dividing. Jia Liu et al. demonstrated that synchronizing a cell population at the G2/M phase using pharmacological agents yields a Sensitizing Enhancement Ratio (SER) of up to 1.42 (Fenofibrate Increases Radiosensitivity in Head and Neck Squamous Cell Carcinoma via Inducing G2/M Arrest and Apoptosis). By preventing cells from progressing past this point, the treatment ensures that radiation-induced double-strand breaks accumulate without the possibility of repair, drastically increasing the probability of cell death.